Benzinga | May 6, 2021 06:46AM EDT

AdaptHealth Raises FY21 Sales Guidance From $2.18B-$2.35B To $2.22B-$2.39B vs $2.29B Est.

Increased Guidance

While it remains difficult to predict the duration and impact of the COVID-19 crisis, based on current business and market trends, the Company is increasing its previously issued financial guidance for fiscal year 2021 as follows:

* Net revenue of $2.22 billion to $2.39 billion, up from prior guidance of $2.18 billion to $2.35 billion

* Adjusted EBITDA of $525 million to $565 million, up from prior guidance of $510 million to $550 million; and

* Adjusted EBITDA less Patient Equipment Capex of $330 million to $360 million, up from prior guidance of $320 million to $350 million.